Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2016 Mar 26

PMID 27014270

Citations 243

Authors

Hans Klingemann

Laurent Boissel

Frances Toneguzzo

Affiliations

Soon will be listed here.

Abstract

Natural killer (NK) cells are potent cytotoxic effector cells for cancer therapy and potentially for severe viral infections. However, there are technical challenges to obtain sufficient numbers of functionally active NK cells from a patient's blood since they represent only 10% of the lymphocytes and are often dysfunctional. The alternative is to obtain cells from a healthy donor, which requires depletion of the allogeneic T cells to prevent graft-versus-host reactions. Cytotoxic cell lines have been established from patients with clonal NK-cell lymphoma. Those cells can be expanded in culture in the presence of IL-2. Except for the NK-92 cell line, though, none of the other six known NK cell lines has consistently and reproducibly shown high antitumor cytotoxicity. Only NK-92 cells can easily be genetically manipulated to recognize specific tumor antigens or to augment monoclonal antibody activity through antibody-dependent cellular cytotoxicity. NK-92 is also the only cell line product that has been infused into patients with advanced cancer with clinical benefit and minimal side effects.

Citing Articles

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy.

Dehghan F, Metanat Y, Askarizadeh M, Ahmadi E, Moradi V Front Cell Dev Biol. 2025; 12:1511931.

PMID: 40007761 PMC: 11850336. DOI: 10.3389/fcell.2024.1511931.

Differentiating Induced Pluripotent Stem Cells into Natural Killer Cells for Adoptive Cell Immunotherapies-Comparative Characterization of Current Protocols.

Budagova T, Efremova A, Usman N, Mokrousova D, Goldshtein D Int J Mol Sci. 2025; 26(3).

PMID: 39940874 PMC: 11816922. DOI: 10.3390/ijms26031107.

Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma.

Nakamura M, Tanaka Y, Hakoda K, Ohira M, Kobayashi T, Kurachi K Cancer Immunol Immunother. 2025; 74(3):99.

PMID: 39904787 PMC: 11794780. DOI: 10.1007/s00262-025-03940-5.

Research Progress of NK Cells in Glioblastoma Treatment.

Wu H, Liu Q, Wang F, Gao W, Zhou F, Zhao H Onco Targets Ther. 2025; 18():87-106.

PMID: 39845286 PMC: 11752833. DOI: 10.2147/OTT.S486411.

CRISPR knock-in of a chimeric antigen receptor into GAPDH 3'UTR locus generates potent B7H3-specific NK-92MI cells.

Dai L, Zhang P, Niu X, Peng X, Suleiman R, Zhang G Cancer Gene Ther. 2025; 32(2):227-239.

PMID: 39833547 DOI: 10.1038/s41417-025-00872-1.

References

Nagata H, Konno A, Kimura N, Zhang Y, Kimura M, Demachi A . Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 2001; 97(3):708-13. DOI: 10.1182/blood.v97.3.708. View

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3):754-8. DOI: 10.1182/blood.v99.3.754. View

Robertson M, Cochran K, Cameron C, Le J, Tantravahi R, Ritz J . Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996; 24(3):406-15. View

Son C, Keum J, Yang K, Nam J, Kim M, Kim S . Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation. Radiat Oncol. 2014; 9:49. PMC: 3923253. DOI: 10.1186/1748-717X-9-49. View

Boissel L, Betancur-Boissel M, Lu W, Krause D, Van Etten R, Wels W . Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology. 2014; 2(10):e26527. PMC: 3881109. DOI: 10.4161/onci.26527. View

Klingemann H . Are natural killer cells superior CAR drivers?. Oncoimmunology. 2014; 3:e28147. PMC: 4203506. DOI: 10.4161/onci.28147. View

Zhang G, Liu R, Zhu X, Wang L, Ma J, Han H . Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol. 2013; 91(10):615-24. DOI: 10.1038/icb.2013.45. View

Maki G, Klingemann H, Martinson J, Tam Y . Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001; 10(3):369-83. DOI: 10.1089/152581601750288975. View

Yagita M, Huang C, Umehara H, Matsuo Y, Tabata R, Miyake M . A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000; 14(5):922-30. DOI: 10.1038/sj.leu.2401769. View

10.

Sahm C, Schonfeld K, Wels W . Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother. 2012; 61(9):1451-61. PMC: 11029748. DOI: 10.1007/s00262-012-1212-x. View

11.

Klingemann H, Wong E, Maki G . A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant. 1996; 2(2):68-75. View

12.

Swift B, Williams B, Kosaka Y, Wang X, Medin J, Viswanathan S . Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica. 2012; 97(7):1020-8. PMC: 3396673. DOI: 10.3324/haematol.2011.054254. View

13.

Chu J, Deng Y, Benson D, He S, Hughes T, Zhang J . CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2013; 28(4):917-27. PMC: 3967004. DOI: 10.1038/leu.2013.279. View

14.

Woll P, Martin C, Miller J, Kaufman D . Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol. 2005; 175(8):5095-103. DOI: 10.4049/jimmunol.175.8.5095. View

15.

Kochenderfer J, Dudley M, Feldman S, Wilson W, Spaner D, Maric I . B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2011; 119(12):2709-20. PMC: 3327450. DOI: 10.1182/blood-2011-10-384388. View

16.

Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell L . CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38. PMC: 3742551. DOI: 10.1126/scitranslmed.3005930. View

17.

Tam Y, Miyagawa B, Ho V, Klingemann H . Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother. 1999; 8(3):281-90. DOI: 10.1089/106161299320316. View

18.

Gong J, Maki G, Klingemann H . Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994; 8(4):652-8. View

19.

Tonn T, Schwabe D, Klingemann H, Becker S, Esser R, Koehl U . Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013; 15(12):1563-70. DOI: 10.1016/j.jcyt.2013.06.017. View

20.

Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F . Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009; 27(7):1122-9. DOI: 10.1200/JCO.2008.18.0463. View